US 11,654,180 B2
Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
Taylor Schreiber, Durham, NC (US); George Fromm, Durham, NC (US); Suresh De Silva, Durham, NC (US); and Neal Schilling, Durham, NC (US)
Assigned to Heat Biologies, Inc., Durham, NC (US)
Filed by Heat Biologics, Inc., Durham, NC (US)
Filed on Apr. 8, 2020, as Appl. No. 16/843,029.
Application 16/843,029 is a continuation of application No. 16/813,165, filed on Mar. 9, 2020.
Application 16/813,165 is a continuation of application No. 16/024,214, filed on Jun. 29, 2018, granted, now 10,646,545.
Application 16/024,214 is a continuation of application No. 15/853,241, filed on Dec. 22, 2017, granted, now 10,188,701, issued on Jan. 29, 2019.
Application 15/853,241 is a continuation of application No. 15/804,533, filed on Nov. 6, 2017, granted, now 10,086,042, issued on Oct. 2, 2018.
Application 15/804,533 is a continuation of application No. 15/281,196, filed on Sep. 30, 2016, granted, now 10,183,060, issued on Jan. 22, 2019.
Claims priority of provisional application 62/372,574, filed on Aug. 9, 2016.
Claims priority of provisional application 62/263,313, filed on Dec. 4, 2015.
Claims priority of provisional application 62/235,727, filed on Oct. 1, 2015.
Prior Publication US 2020/0261537 A1, Aug. 20, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); C07K 14/00 (2006.01); C07K 19/00 (2006.01); A61K 38/00 (2006.01)
CPC A61K 38/1774 (2013.01) [A61K 38/177 (2013.01); C07K 14/00 (2013.01); C07K 19/00 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/74 (2013.01); Y02A 50/30 (2018.01)] 23 Claims
 
1. A heterologous chimeric protein comprising a first domain linked to a second domain, wherein the first domain comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 33 and is capable of binding human CD47 and the second domain comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 60 and is capable of binding human CD40, wherein the first domain and the second domain are linked by a linker positioned between and adjoining the first domain and the second domain, the linker being a polypeptide comprising a flexible amino acid sequence.